Rastogi, Anjay

Effect of intensive blood pressure treatment on heart failure events in the systolic blood pressure reduction intervention trial

Upadhya, B., Rocco, M., Lewis, C. E., Oparil, S., Lovato, L. C., Cushman, W. C., Bates, J. T., Bello, N. A., Aurigemma, G., Fine, L. J., et al. (2017) · Circulation: Heart Failure

Blood Pressure and Hypertension StudiesHeart Failure Treatment and Management

Cited by 118

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis

Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 109

Reduction of serum hepcidin by hemodialysis in pediatric and adult patients

Zaritsky, J., Young, B., Gales, B., Wang, H.-J., Rastogi, A., Westerman, M., Nemeth, E., Ganz, T., & Salusky, I. B. (2010) · Clinical Journal of the American Society of Nephrology

Iron Metabolism and DisordersErythropoietin and Anemia Treatment

Cited by 107

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Heerspink, H. J. L., Jardine, M. J., Kohan, D. E., Lafayette, R., Levin, A., Liew, A., Zhang, H., Noronha, I. L., Mastroianni-Kirsztajn, G., Chow, S., et al. (2026) · The Lancet

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 12